Assessment of drug-related migraine in a real-world large-scale database.

This large-scale analysis identifies key drug categories and compounds associated with an elevated risk of migraine, providing actionable insights for clinicians. Especially lorcaserin, tasimelteon, and botulinum toxin as potential risk factors for migraine. Given the public health burden of migraine, pharmacovigilance efforts should incorporate such findings to mitigate iatrogenic risks. Further prospective studies are warranted to establish causal mechanisms and optimize therapeutic decision-making.